Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Bristol Myers Squibb
Bristol Myers Squibb
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
BioPharma Dive
Bristol Myers Squibb
Opdivo
non-small cell lung cancer
clinical trials
Flag link:
Samsung Biologics adds to BMS manufacturing partnership with new $242M antibody agreement
Samsung Biologics adds to BMS manufacturing partnership with new $242M antibody agreement
Fierce Pharma
Samsung BioLogics
Bristol Myers Squibb
drug manufacturing
antibodies
Flag link:
Bristol Myers plans to double experimental treatments to expand research pipeline
Bristol Myers plans to double experimental treatments to expand research pipeline
Yahoo/Reuters
Bristol Myers Squibb
clinical trials
R&D
Flag link:
Xspray, seeking FDA approval for its Sprycel competitor, settles patent lawsuit with BMS
Xspray, seeking FDA approval for its Sprycel competitor, settles patent lawsuit with BMS
Fierce Pharma
Xspray Pharma
FDA
Sprycel
Bristol Myers Squibb
Dasynoc
Flag link:
Bristol Myers Squibb reports results from Phase II study of BMS-986278
Bristol Myers Squibb reports results from Phase II study of BMS-986278
Clinical Trials Arena
Bristol Myers Squibb
clinical trials
progressive pulmonary fibrosis
BMS-986278
Flag link:
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit
Reuters
Bristol Myers Squibb
Celgene
patents
legal
Pomalyst
Flag link:
BMS publishes 'modest' multiple myeloma survival data on heir to Revlimid, Pomalyst
BMS publishes 'modest' multiple myeloma survival data on heir to Revlimid, Pomalyst
Fierce Biotech
Bristol Myers Squibb
Revlimid
Pomalyst
Multiple Myeloma
mezigdomide
Flag link:
Bristol Myers gets key FDA approval for bone marrow disease drug
Bristol Myers gets key FDA approval for bone marrow disease drug
BioPharma Dive
Bristol Myers Squibb
FDA
Reblozyl
myelodysplastic syndromes
Flag link:
Biden administration lists 10 drugs for Medicare price negotiation
Biden administration lists 10 drugs for Medicare price negotiation
Medical Marketing and Media
Medicare
HHS
Pfizer
Bristol Myers Squibb
Eli Lilly
Boehringer Ingelheim
AstraZeneca
AbbVie
Novo Nordisk
JNJ
drug pricing
Flag link:
BMS backs $255m round for contract cell maker Cellares
BMS backs $255m round for contract cell maker Cellares
Pharmaphorum
Cellares
funding
cell therapy
Bristol Myers Squibb
Flag link:
Fierce Biotech Layoff Tracker 2023: Bayer-bought BlueRock makes cuts; Alaunos lets go 60% of teams
Fierce Biotech Layoff Tracker 2023: Bayer-bought BlueRock makes cuts; Alaunos lets go 60% of teams
Fierce Biotech
layoffs
Alaunos Therapeutics
BlueRock Therapeutics
Thermo Fisher
Bristol Myers Squibb
Atreca
Galera Therapeutics
Inovio
Salarius Pharmaceuticals
Karyopharm Therapeutics
Intergalatic Therapeutics
Flag link:
The 10 drugs that CMS might wrangle into negotiations
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Flag link:
Another round of layoffs hits BMS, with 100+ people impacted after earnings miss
Another round of layoffs hits BMS, with 100+ people impacted after earnings miss
Fierce Pharma
Bristol Myers Squibb
layoffs
Flag link:
BMS debuts ‘We Are Bristol Myers Squibb’ video
BMS debuts ‘We Are Bristol Myers Squibb’ video
Medical Marketing and Media
Bristol Myers Squibb
branding
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Flag link:
Eliquis: the cardio drug that cannot be beat
Eliquis: the cardio drug that cannot be beat
EP Vantage
Bristol Myers Squibb
Eliquis
generics
Flag link:
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban
Fierce Pharma
Bristol Myers Squibb
BeiGene
Celgene
Flag link:
Bristol Myers, AstraZeneca settle PD-1, CTLA-4 cancer immunotherapy patent suits for $510M
Bristol Myers, AstraZeneca settle PD-1, CTLA-4 cancer immunotherapy patent suits for $510M
Fierce Pharma
Bristol Myers Squibb
AstraZeneca
cancer immunotherapy
legal
patents
Patent Infringement
Flag link:
Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
Reuters
injectables
cancer
JNJ
Bristol Myers Squibb
Halozyme
drug pricing
Flag link:
BMS Reports Q2 Sales Miss Amid Generic Competition, Lowers Full-Year Guidance
BMS Reports Q2 Sales Miss Amid Generic Competition, Lowers Full-Year Guidance
BioSpace
Bristol Myers Squibb
earnings
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »